Related Experiment Video
Updated: Nov 25, 2025
08:39
Ex Vivo Release of Calcitonin Gene-Related Peptide from the Trigeminovascular System in Rodents
Published on: May 16, 2022
2.7K
Rimegepant for the treatment of migraine
1Regional Referral Headache Centre, Department of Clinical and Molecular Medicine, Sant'Andrea Hospital, Sapienza University, Rome, Italy. andrea.negro@uniroma1.it.
Drugs of Today (Barcelona, Spain : 1998)
|December 17, 2020
Summary
Rimegepant, an oral CGRP receptor antagonist, effectively treats acute migraine with a single dose, offering sustained relief and good tolerability. It is FDA-approved for migraine headache acute treatment.
Area of Science:
- Pharmacology
- Neurology
- Clinical Trials
Background:
- Migraine is a debilitating neurological condition.
- Calcitonin gene-related peptide (CGRP) receptor antagonists represent a novel therapeutic class for migraine.
- Rimegepant offers a new oral formulation for acute migraine treatment.
Purpose of the Study:
- To evaluate the efficacy and safety of rimegepant for acute migraine treatment.
- To assess the sustained effect and tolerability of rimegepant.
- To report on the FDA approval status and ongoing clinical trials.
Main Methods:
- Phase II and III clinical trials were completed.
- Efficacy endpoints included pain freedom, pain relief, symptom reduction, and lifestyle recovery.
- Safety and tolerability were assessed through adverse event monitoring.
Main Results:
- Rimegepant demonstrated significant clinical efficacy in single-dose studies.
- Sustained relief was observed up to 48 hours post-administration.
- The drug was well-tolerated, with mild to moderate adverse events.
Conclusions:
- Rimegepant is an effective and well-tolerated treatment for acute migraine.
- FDA approval signifies its clinical utility for migraine headache.
- Ongoing trials will further define its role in migraine management and other conditions.
Related Concept Videos
01:20Antiepileptic Drugs: Potassium Channel Activators
448
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
448
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
340
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
340
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
386
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
386
01:14Antiepileptic Drugs: Glutamate Antagonists
708
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
708
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
461
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
461
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
328
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
328